Paul Goldberg

Paul Goldberg

Editor & Publisher

Paul Goldberg is the editor and publisher of The Cancer Letter. He joined the publication in 1986.

His coverage has had a profound impact on the field of oncology, leading to numerous Congressional investigations, and helped change policy, regulation, and standards of care.

Paul’s reporting has been recognized by the Washington DC Professional Chapter of the Society of Professional Journalists, the Gerald Loeb Awards, the Association of Health Care Journalists, and the Newsletter and Electronic Publishers Foundation.

His articles have appeared in The New York Times, The Wall Street Journal, The Washington Post and The Washington Monthly, and he has been featured on 60 Minutes, 20/20, CNN and NPR. He is also a novelist and author of nonfiction books.

His author website is www.paulgoldberg.com. 

Paul graduated from Duke University with a B.A. in economics in 1981.
Books
Latest Stories
CMS rule cuts overall oncology payments by estimated 2% Final rule slashes 340B, moves toward site-neutrality
The Centers for Medicare and Medicaid Services last week published the long-awaited—or long-dreaded—final rule governing Medicare reimbursement of the Hospital Outpatient Prospective Payment System.
Democrats vow to undo Trump’s Medicaid cuts, reverse ACA dismantling
News Analysis
In a victory speech on Nov. 4, Rep. Hakeem Jeffries (D-NY), the presumed next speaker of the House, ran through the bread-and-butter concerns which gave Democrats House and Senate majorities not seen in a generation.
NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises New NOFO aims to shrink applications by 40%
NCI
Late next month, NCI is expected to publish the new criteria it uses to bestow designations on America’s network of cancer centers.
VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs Center directors are strategizing for likely FDA approval of GRAIL’s Galleri
The Directors
As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly. 
As trust in USPSTF erodes, cancer screening is in peril David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines
Conversation with The Cancer Letter

The U.S. Preventive Services Task Force is at risk of losing the expertise, evidence-review infrastructure, and institutional culture that has made it a model for evidence-based medicine. In July 2025, David Ransohoff, a gastroenterologist and clinical epidemiologist in the Division of Gastroenterology and Hepatology at University of North Carolina School of Medicine, noted that HHS...

With Year One metrics in hand, Letai is ready to “bring it home” in Year Two “I hope I don’t see any more reports of NCI cutting funding, because it just is not consistent with the facts”
Conversation with The Cancer Letter
A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login